Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MTAP and p16 IHC as Markers for CDKN2A/B Loss in Meningiomas

27 Sept 2024

Abstract excerpt

Background: Homozygous cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) loss is one of the parameters that support the designation of meningiomas as Central Nervous System (CNS) WHO grade 3 tumors. Evaluation of CDKN2A/B by sequencing or Fluorescence in situ hybridization (FISH) is costly and not always readily accessible. An immunohistochemistry (IHC)-based marker for the evaluation of CDKN2A/B loss would...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glioma Diagnosis and Treatment
Share to Meningioma and schwannoma management
Share to Neurofibromatosis and Schwannoma Cases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39409918
DOI: 10.3390/cancers16193299

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MTAP and p16 IHC as Markers for CDKN2A/B Loss in MeningiomasPMID 39409918Read ↗

Molecular prognostication in grade 3 meningiomas and p16/MTAP immunohistochemistry for predicting CDKN2A/B statusSemantic proximity Read ↗

[Pathological Diagnosis and Genetic Alterations of Meningioma].Semantic proximity Read ↗

Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomasSemantic proximity Read ↗

Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomasSemantic proximity Read ↗

European Association of Neuro-Oncology guideline on molecular testing of meningiomas for targeted therapy selectionSemantic proximity Read ↗

Meningioma Grading beyond Histopathology: Relevance of Epigenetic and Genetic Features to Predict Clinical OutcomeSemantic proximity Read ↗

Molecular alterations in meningioma: prognostic and therapeutic perspectivesSemantic proximity Read ↗

DNA methylation meningioma biomarkers: attributes and limitationsSemantic proximity Read ↗

DNA methylation profiling of meningiomas highlights clinically distinct molecular subgroups.Semantic proximity Read ↗

Meningioma: A Pathology Perspective.Semantic proximity Read ↗

Advances in Molecular Classification and Therapeutic Opportunities in Meningiomas.Semantic proximity Read ↗

Identification of PD-L2, B7-H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningiomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.